Evotec AG‘s strategic alliance with Celgene has reached another important scientific achievement, resulting in Celgene designating a program and triggering a $14M milestone payment  to Evotec.    The payment was received by year-end 2018. This scientific achievement was the advancement of a program into the lead optimization stage developed from Evotec’s compound library using its induced pluripotent stem cell (“iPSC”)-based screening platform. This program can be...